What Does Global Blood Therapeutics Do?

Total employees92
HeadquartersSouth San Francisco
Founded2011

Global Blood Therapeutics (GBT) was a biopharmaceutical company focused on the discovery, development, and delivery of life-changing treatments for patients with grievous, underserved blood-based disorders, with an initial focus on sickle cell disease (SCD). Their lead product, Oxbryta® (voxelotor), was the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization. In October 2022, Global Blood Therapeutics was acquired by Pfizer Inc., and its operations and pipeline, including Oxbryta, are now integrated into Pfizer's Rare Disease portfolio. GBT's mission was to transform the treatment and care of SCD.

Where Is Global Blood Therapeutics's Headquarters?

HQ Function

Served as the central hub for Global Blood Therapeutics' research and development, corporate operations, and strategic management prior to its acquisition by Pfizer.

Notable Features:

Located in a prominent biotech hub in South San Francisco, providing access to a rich ecosystem of talent and innovation. The facilities were designed to support both office-based work and laboratory research.

Work Culture:

GBT was known for its patient-focused and science-driven culture, with a strong mission to develop innovative treatments for underserved patient communities, particularly those affected by sickle cell disease. The culture emphasized collaboration and a commitment to making a difference in patients' lives.

HQ Significance:

The South San Francisco headquarters was pivotal to GBT's journey, housing the leadership and core teams that successfully advanced Oxbryta from clinical development to regulatory approval and commercialization, and managed the company's pipeline of potential SCD therapies.

Values Reflected in HQ: The headquarters' location in a leading biotech innovation center reflected GBT's commitment to cutting-edge science. The internal environment was designed to foster collaboration, urgency, and a deep focus on their mission to serve patients with sickle cell disease.

Location:

Prior to its acquisition by Pfizer, Global Blood Therapeutics was actively expanding its global presence to address sickle cell disease, a worldwide health issue. Key functions supported globally included conducting multinational clinical trials for its drug candidates, establishing a European headquarters in Switzerland to oversee operations in Europe, engaging with international regulatory bodies for drug approvals, and planning for the commercial launch and distribution of its therapies in key international markets beyond the United States. Their efforts were primarily focused on regions with significant sickle cell disease populations.

Street Address:

171 Oyster Point Blvd, Suite 300

City:

South San Francisco

State/Province:

California

Country:

USA

Where Else Does Global Blood Therapeutics Operate Around the World?

Baar, Zug, Switzerland

Address: Haldenstrasse 5, CH-6340 Baar, Switzerland

To establish and expand GBT's operational presence in Europe, facilitate engagement with European health authorities and key opinion leaders, and support market access and commercial launch strategies for its treatments for sickle cell disease patients in the region.

Buying Intent Signals for Global Blood Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Global Blood Therapeutics? Meet the Executive Team

As of April 2025, Global Blood Therapeutics' leadership includes:

Ted W. Love, M.D. - President and Chief Executive Officer
Jeffrey Farrow - Chief Financial Officer and Head of Corporate Development
David L. (D.J.) Johnson - Chief Commercial Officer
Jung E. Choi - Chief Business and Strategy Officer and Head of Technical Operations
Eric M. Fink, J.D., Ph.D. - Chief Legal Officer and Corporate Secretary

Who's Investing in Global Blood Therapeutics?

Global Blood Therapeutics has been backed by several prominent investors over the years, including:

Third Rock Ventures
TPG Biotech
Fidelity Management & Research Company
Wellington Management Company

What Leadership Changes Has Global Blood Therapeutics Seen Recently?

Hire0
Exits0

Following Pfizer's acquisition of Global Blood Therapeutics, completed in October 2022, the GBT executive team largely transitioned out of their roles as the company and its operations were integrated into Pfizer. This marked the most significant leadership change for GBT. As GBT no longer operates as an independent entity, there have been no executive hires or exits specifically for 'Global Blood Therapeutics' in the last 12 months (e.g., May 2023 - May 2024).

Departures

Ted W. Love, M.D., Stepped down following Pfizer's acquisition of Global Blood Therapeutics.
Jeffrey Farrow, Departed GBT leadership role post-acquisition by Pfizer.
David L. (D.J.) Johnson, Departed GBT leadership role post-acquisition by Pfizer.

New Appointments:

N/A, Global Blood Therapeutics does not make new appointments as an independent entity following its acquisition by Pfizer in October 2022.

What Technology (Tech Stack) Is Used byGlobal Blood Therapeutics?

Discover the tools Global Blood Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Global Blood Therapeutics Email Formats and Examples

Prior to its acquisition by Pfizer, Global Blood Therapeutics likely used common corporate email formats. For example, emails were often structured as the first initial followed by the last name, or first name followed by a period and then last name. As GBT is now part of Pfizer, GBT-specific email addresses (e.g., @gbt.com) are no longer active.

[first_initial][last]@gbt.com or [first].[last]@gbt.com

Format

jdoe@gbt.com or jane.doe@gbt.com (historical example)

Example

0 (GBT email domain is no longer in active use post-acquisition)%

Success rate

What's the Latest News About Global Blood Therapeutics?

Pfizer Press ReleaseOctober 5, 2022

Pfizer Completes Acquisition of Global Blood Therapeutics

Pfizer Inc. announced the successful completion of its acquisition of Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments for sickle cell disease (SCD)....more

Pfizer Press ReleaseAugust 8, 2022

Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology

Pfizer Inc. and Global Blood Therapeutics, Inc. announced that the companies have entered into a definitive agreement under which Pfizer will acquire GBT. This acquisition was intended to complement and enhance Pfizer’s more than 30-year heritage in rare hematology....more

GBT Press Release (archived)June 10, 2022

Global Blood Therapeutics Presents New Data on Inclacumab and Voxelotor at EHA2022 Congress

GBT announced new data presentations on inclacumab, its investigational P-selectin inhibitor, and voxelotor (Oxbryta), its approved therapy for sickle cell disease, at the European Hematology Association (EHA) 2022 Hybrid Congress. The data highlighted the potential of these therapies to address unmet needs in SCD....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Global Blood Therapeutics, are just a search away.